JP2017515849A - Ａｄｈｄを治療するためのダソトラリン用量および治療方法 - Google Patents

Ａｄｈｄを治療するためのダソトラリン用量および治療方法 Download PDF

Info

Publication number
JP2017515849A
JP2017515849A JP2016567529A JP2016567529A JP2017515849A JP 2017515849 A JP2017515849 A JP 2017515849A JP 2016567529 A JP2016567529 A JP 2016567529A JP 2016567529 A JP2016567529 A JP 2016567529A JP 2017515849 A JP2017515849 A JP 2017515849A
Authority
JP
Japan
Prior art keywords
dasotraline
acid
adhd
treatment
methylphenidate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016567529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515849A5 (enExample
Inventor
アントニー・ディ・ローベル
ケネス・エス・コブラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of JP2017515849A publication Critical patent/JP2017515849A/ja
Publication of JP2017515849A5 publication Critical patent/JP2017515849A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016567529A 2014-05-13 2015-05-12 Ａｄｈｄを治療するためのダソトラリン用量および治療方法 Pending JP2017515849A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992619P 2014-05-13 2014-05-13
US61/992,619 2014-05-13
PCT/US2015/030357 WO2015175523A1 (en) 2014-05-13 2015-05-12 Dosage of dasotraline and method for treatment of adhd

Publications (2)

Publication Number Publication Date
JP2017515849A true JP2017515849A (ja) 2017-06-15
JP2017515849A5 JP2017515849A5 (enExample) 2018-06-21

Family

ID=54480549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567529A Pending JP2017515849A (ja) 2014-05-13 2015-05-12 Ａｄｈｄを治療するためのダソトラリン用量および治療方法

Country Status (10)

Country Link
US (1) US10076503B2 (enExample)
EP (1) EP3143000A4 (enExample)
JP (1) JP2017515849A (enExample)
KR (1) KR20170005088A (enExample)
CN (1) CN106660937A (enExample)
AU (1) AU2015259346A1 (enExample)
CA (1) CA2948839A1 (enExample)
IL (1) IL248847A0 (enExample)
MX (1) MX2016014768A (enExample)
WO (1) WO2015175523A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210386689A1 (en) * 2018-10-31 2021-12-16 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512921A (ja) * 2009-12-04 2013-04-18 スノビオン プハルマセウトイカルス インコーポレイテッド トランスノルセルトラリンの製剤、塩、及び多形体、並びにその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
PT1542961E (pt) * 2002-09-16 2013-11-05 Sunovion Pharmaceuticals Inc Trans 4-(3,4-diclorofenil)-1,2,3,4-tetrahidro-1- naftalenamina para uso no tratamento de perturbações do sistema nervoso central

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512921A (ja) * 2009-12-04 2013-04-18 スノビオン プハルマセウトイカルス インコーポレイテッド トランスノルセルトラリンの製剤、塩、及び多形体、並びにその使用

Also Published As

Publication number Publication date
US20170266134A1 (en) 2017-09-21
MX2016014768A (es) 2017-03-06
US10076503B2 (en) 2018-09-18
KR20170005088A (ko) 2017-01-11
EP3143000A1 (en) 2017-03-22
CN106660937A (zh) 2017-05-10
CA2948839A1 (en) 2015-11-19
IL248847A0 (en) 2017-01-31
WO2015175523A1 (en) 2015-11-19
AU2015259346A1 (en) 2016-12-08
EP3143000A4 (en) 2017-12-13

Similar Documents

Publication Publication Date Title
Houser et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly
Donohue et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol
Biederman et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD
JP2021098743A (ja) 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
AU2018342072B2 (en) Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
US20190247333A1 (en) Method of reduction in convulsive seizure frequency
KR102649644B1 (ko) 편두통 예방을 위한 라스미디탄의 만성 야간 투여
WO2016044150A1 (en) VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
Koblan et al. Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users
Paton Deutetrabenazine: treatment of hyperkinetic aspects of Huntington’s disease, tardive dyskinesia and Tourette syndrome
CN119174751A (zh) 用于治疗焦虑相关病症的组合物和方法
Al‐Qassab et al. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study
JP2017515858A (ja) Ａｄｈｄの治療のためのダソトラリンに関する方法および組成物
TW473388B (en) Pharmaceutical composition comprising a carnitine derivative for treating Alzheimer's disease in early-onset patients
Glazer et al. The treatment of tardive dyskinesia with baclofen
JP2017515849A (ja) Ａｄｈｄを治療するためのダソトラリン用量および治療方法
Pezawas et al. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance
KR20240027750A (ko) 뇌성 마비로 인한 이상운동증 치료용 발베나진
JP2023526634A (ja) 高アンモニア血症を治療するためのオルニチンフェニルアセテートの使用
US8222278B2 (en) Treatment of attention-deficit/hyperactivity disorder
Weiden et al. 167 randomized, double-blind, active-controlled study of starting aripiprazole lauroxil with 1-day initiation in acutely ill patients with schizophrenia
Lipavský P. 1.075 Citalopram in depressed cardiac patients
Poole Atomoxetine: long-term treatment benefits in ADHD
Tiseo et al. P. 4.023 The pharmacokinetics and pharmacodynamics of (R)-and (S)-Warfarin are unaffected by co-administration of donepezil
Bondolfi et al. Fluoxetine addition to risperidone in adult psychotic patients: Pharmacokinstic and clinical consequences

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191015